Marketing attribution best practices for 2026 for healthcare and life sciences in Latin America
The current, revised best practices for marketing attribution — updated for what actually works in the buyer environment of 2026. Written for commercial leaders at healthtech, medtech, and life-sciences companies in Latin America.
This edition of the Growth Broker playbook is written for commercial leaders at healthtech, medtech, and life-sciences companies operating in Latin America. In this market, LATAM buyers reward hands-on partnership, local presence, and clear commercial terms, so the way you install marketing attribution has to be shaped to that reality from day one.
Best practices for marketing attribution have shifted. The 2022 playbook does not survive the current buyer environment. This is the update.
Best practice one: fewer accounts, sharper triggers. You cannot allocate spend against a number you don't trust, and generic coverage is now negative signal.
Best practice two: publish attribution model reconciled to closed-won weekly. If leadership does not see the number, the model quietly drifts.
Inside healthcare and life sciences, the binding constraint is almost always regulated-sale cycle length, not intent, and in Latin America it is compounded by the fact that local partnership depth, not marketing spend is what actually gates growth. Marketing attribution is only useful here when it is pointed at both constraints at once.
Best practice three: separate the sending infrastructure from the primary brand. Deliverability is a strategic asset.
Best practice four: name a single owner. Committees produce compromise; owners produce numbers.
Best practice five: pre-write kill criteria. A stated failure threshold is what prevents the sunk-cost trap.
Best practice six: run monthly retrospectives that are honest about what did not work. Marketing attribution improves faster on failure data than on success data.
Concretely for healthcare and life sciences in Latin America: the healthcare teams that install this get past procurement instead of dying in it, and one properly-installed LATAM account becomes a reference across the region. That is the reason it is worth installing marketing attribution deliberately for this market rather than importing a playbook designed for somewhere else.
Frequently asked questions
Measurement · healthcare · LATAM — answered
- Does marketing attribution work for healthcare and life sciences in Latin America?
- Yes — provided it is pointed at regulated-sale cycle length, not intent and adapted to the fact that in Latin America, LATAM buyers reward hands-on partnership, local presence, and clear commercial terms. The healthcare teams that install this get past procurement instead of dying in it.
- What changed in marketing attribution best practices for 2026?
- Buyers are less tolerant of generic coverage; specificity and trigger quality now dominate.
- Which best practice is most under-implemented?
- Pre-written kill criteria. Almost no team has them; every team benefits from them.
- Do best practices change by company size?
- Governance scales with size; core principles remain identical.
- How do I know a best practice is working?
- Attribution model reconciled to closed-won improves, and improvements survive a month.
- What is the LATAM-specific pitfall when running marketing attribution for healthcare?
- Importing a playbook that was built for another market. In Latin America, LATAM buyers reward hands-on partnership, local presence, and clear commercial terms — the install has to reflect that.
Growth Broker editorial
Filed under measurement · healthcare · latam